Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses.
Reid KT, Colpitts SJ, Mathews JA, Santos Carreira A, Murphy JM, Borovsky DT, Jegatheeswaran S, Cui W, Alfaro Moya T, Sachewsky N, An J, Xia Y, Mortha A, Lee JB, Zhang L, Novitzky-Basso I, Mattsson J, Crome SQ.
Reid KT, et al. Among authors: cui w.
Cell Rep. 2024 Dec 24;44(1):115102. doi: 10.1016/j.celrep.2024.115102. Online ahead of print.
Cell Rep. 2024.
PMID: 39721022